NASDAQ:NOVN - Novan Stock Price, Forecast & News

Novan trades on the NASDAQ under the ticker symbol "NOVN."

Novan Inc (NASDAQ:NOVN) posted its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.32) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.42) by $0.10. The business had revenue of $1.32 million for the quarter, compared to the consensus estimate of $1.20 million. View Novan's Earnings History.

Novan is scheduled to release their next quarterly earnings announcement on Wednesday, March 25th 2020. View Earnings Estimates for Novan.

3 analysts have issued twelve-month price objectives for Novan's shares. Their forecasts range from $0.50 to $1.50. On average, they expect Novan's share price to reach $1.00 in the next year. This suggests a possible upside of 47.5% from the stock's current price. View Analyst Price Targets for Novan.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novan in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Novan.

News headlines about NOVN stock have trended extremely negative on Sunday, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Novan earned a news impact score of -4.5 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the next few days. View News Stories for Novan.

Novan saw a increase in short interest in December. As of December 31st, there was short interest totalling 847,400 shares, an increase of 24.6% from the December 15th total of 680,300 shares. Based on an average daily volume of 261,800 shares, the short-interest ratio is presently 3.2 days. Currently, 5.0% of the company's stock are short sold. View Novan's Current Options Chain.

Some companies that are related to Novan include CNS Pharmaceuticals (CNSP), Tiziana Life Sciences (TLSA), Chembio Diagnostics (CEMI), AgeX Therapeutics (AGE), Aridis Pharmaceuticals (ARDS), Entasis Therapeutics (ETTX), Aclaris Therapeutics (ACRS), Sunesis Pharmaceuticals (SNSS), Kezar Life Sciences (KZR), Acasti Pharma (ACST), Soligenix (SNGX), Alpine Immune Sciences (ALPN), SCYNEXIS (SCYX), Onconova Therapeutics (ONTX) and resTORbio (TORC).

Based on aggregate information from My MarketBeat watchlists, some companies that other Novan investors own include Melinta Therapeutics (MLNT), Valero Energy (VLO), Biocept (BIOC), Cirrus Logic (CRUS), Heron Therapeutics (HRTX), Intuitive Surgical (ISRG), NovaBay Pharmaceuticals (NBY), Advanced Micro Devices (AMD), Catalyst Biosciences (CBIO) and Gilead Sciences (GILD).

(NOVN) raised $46 million in an initial public offering (IPO) on Wednesday, September 21st 2016. The company issued 3,800,000 shares at $11.00-$13.00 per share. Piper Jaffray served as the underwriter for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Novan's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Cardinal Capital Management (0.19%) and Vigilant Capital Management LLC (0.11%). Company insiders that own Novan stock include G Kelly Martin, John M Gay, John W Palmour, Life Sciences Holdings L Malin, Paula B Stafford and Robert Alexander Ingram. View Institutional Ownership Trends for Novan.

NOVN stock was acquired by a variety of institutional investors in the last quarter, including Cardinal Capital Management and Vigilant Capital Management LLC. Company insiders that have bought Novan stock in the last two years include G Kelly Martin, John M Gay, John W Palmour, Paula B Stafford and Robert Alexander Ingram. View Insider Buying and Selling for Novan.

Shares of NOVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NOVN stock can currently be purchased for approximately $0.68.

Novan has a market capitalization of $18.12 million and generates $5.99 million in revenue each year. The company earns $-12,670,000.00 in net income (profit) each year or ($1.13) on an earnings per share basis. Novan employs 47 workers across the globe.View Additional Information About Novan.

The official website for Novan is http://www.novantherapeutics.com/.

Novan's mailing address is 4105 HOPSON ROAD, MORRISVILLE NC, 27560. The company can be reached via phone at 919-485-8080 or via email at [email protected]